title: External validation of the cancer of the prostate risk assessment (CAPRA) score in a single-surgeon radical prostatectomy series.
abstract: OBJECTIVE
  Prostate cancer clinical staging has significant limitations in the ability to accurately risk-stratify patients for prompt treatment or expectant management. The University of California San Francisco Cancer of the Prostate Risk Assessment (UCSF CAPRA) was recently described as a straightforward staging system that uses clinical variables to generate a score ranging from 0 to 10. Our objective was to perform an external validation of the CAPRA score as a predictor of 5-year progression-free survival (PFS) in a single-surgeon radical retropubic prostatectomy (RRP) series.
  
  
  METHODS
  We examined the performance characteristics of the preoperative CAPRA score (0-10) to predict biochemical progression-free survival (PFS) in 990 men who underwent RRP by a single surgeon from 2003 to 2009.
  
  
  RESULTS
  CAPRA scores were significantly associated with the risk of early biochemical progression in our series. For example, 5-year PFS was markedly different for scores at the extremes of 0 to 1 vs. ≥7 (95% vs. 40%, respectively). The concordance index was 0.764 for the prediction of biochemical progression using CAPRA scores in this cohort, which compares favorably with the concordance index of 0.66 in the original CaPSURE dataset.
  
  
  CONCLUSIONS
  Our results validate the UCSF-CAPRA score as a significant predictor of 5-year PFS in a single surgeon series. The CAPRA score is a simple preoperative tool that can be readily applied in clinical practice to help risk-stratify prostate cancer patients.
authors.affiliation: James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA.
authors.forename: Stacy
authors.initials: S
authors.lastname: Loeb
authors.forename: Gustavo F
authors.initials: GF
authors.lastname: Carvalhal
authors.forename: Donghui
authors.initials: D
authors.lastname: Kan
authors.forename: Angel
authors.initials: A
authors.lastname: Desai
authors.forename: William J
authors.initials: WJ
authors.lastname: Catalona
mesh_terms: D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care / Q000379:methods; D011379:Prognosis; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology / Q000601:surgery*; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000601:surgery*; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D013997:Time Factors
chemical_list: D017430:Prostate-Specific Antigen
references.citation: J Urol. 2005 Jun;173(6):1938-42
references.pmid: 15879786
references.citation: J Urol. 1993 Jul;150(1):110-4
references.pmid: 7685418
references.citation: J Natl Cancer Inst. 1998 May 20;90(10):766-71
references.pmid: 9605647
references.citation: J Urol. 2007 Nov;178(5):1957-62; discussion 1962
references.pmid: 17868719
references.citation: JAMA. 2005 May 4;293(17):2095-101
references.pmid: 15870412
references.citation: J Urol. 2004 Jun;171(6 Pt 1):2255-9
references.pmid: 15126797
references.citation: J Natl Cancer Inst. 2009 Jun 16;101(12):878-87
references.pmid: 19509351
references.citation: N Engl J Med. 2005 May 12;352(19):1977-84
references.pmid: 15888698
references.citation: JAMA. 1998 Sep 16;280(11):969-74
references.pmid: 9749478
references.citation: Cancer. 2006 Nov 15;107(10):2384-91
references.pmid: 17039503
references.citation: Cancer. 2008 Jan 1;112(1):69-74
references.pmid: 18000803
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Urology. 2001 Dec;58(6):843-8
references.pmid: 11744442
references.citation: J Urol. 2005 Apr;173(4):1126-31
references.pmid: 15758720
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4400-7
references.pmid: 18628454
references.citation: Curr Opin Urol. 2008 May;18(3):279-96
references.pmid: 18382238
references.citation: Cancer. 2008 Mar 15;112(6):1254-63
references.pmid: 18286530
references.citation: J Urol. 2004 Dec;172(6 Pt 1):2227-31
references.pmid: 15538237
references.citation: J Urol. 2008 Jun;179(6):2207-10; discussion 2210-1
references.pmid: 18423693
references.citation: Urology. 2008 Aug;72(2):396-400
references.pmid: 18372031